A novel strategy for advanced pancreatic cancer-progression of molecular targeting therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 8, 2009, Pages 877-881

  Osada, Shinji ^a   Yoshida, Kazuhiro ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug delivery system; Endoscopic ultrasound (EUS) guided fine needle injection (FNI); Extracellular signal regulated protein kinase (ERK); Molecular targeting therapy; Pancreas cancer; Vitamin K3 (menadione)

Indexed keywords

ASCORBIC ACID; BOTULINUM TOXIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; GEMCITABINE; MENADIONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOMYCIN C; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CARCINOMA; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENDOSCOPIC ECHOGRAPHY; ENZYME PHOSPHORYLATION; ESOPHAGUS ACHALASIA; GENE TRANSFER; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; PANCREAS CANCER; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

CELL DIVISION; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; VITAMIN K 3;

EID: 73449138367     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789124691     Document Type: Review

References (45)

1. Osada, S.; Imai, H.; Okumura, N.; Tokuyama, Y.; Hosono, Y.; Sakashita, F.; Sugiyama, Y. A modified reconstruction method to prevent critical complications after pancreatoduodenectomy. Hapaogastroeterol, 2006, 53, 296-300.
2. Matsuno, S.; Egawa, S.; Fukuyama, S.; Motoi, F.; Sunamura, M.; Isaji, S.; Imaizumi, T.; Okada, S.; Kato, H.; Suda, K.; Nakao, A.; Hiraoka, T.; Hosotani, R.; Takeda, K. Pancreatic cancer registry in Japan-20 years of experience. Pancreas, 2004, 28, 219-230.
3. Willett, C.G.; Czito, BG.; Bendell, J.C.; Ryan, D.P. Locally advanced pancreatic cancer. J. Clin. Oncol., 2005, 23, 4538-4544.
4. rd.; Moore, M.J.; Andersen, J.; Green, MR.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; von-Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 1997, 15, 2403-2413.
5. Berlin, J.D.; Catalano, P.; Thomas, J.P.; Kugler, J.W.; Haller, D.G.; Benson, A.B. 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol., 2002, 20, 3270-3275.
6. Louvet, C.; Labianca, R.; Hammel, P.; Lledo, G.; Zampino, M.G.; André, T.; Zaniboni, A.; Ducreux, M.; Aitini, E.; Taïeb, J.; Faroux, R.; Lepere, C.; de-Gramont, A. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non-resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup phase III. Proc. Am. Soc. Clin. Oncol., 2004, 23, 4008.
7. Fischer, P.M.; Lane, D.P. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem., 2000, 7, 1213-1245.
8. Bhaskara, A.; Eng, C. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin. Colorectal Cancer, 2008, 7, 65-68.
9. Sederowicz, A.M.; Johnson, J.R.; Sridhara, R.; Zimmerman, P.; Justice, R.; Pazdur, R. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology, 2007, 21, 1696-1706.
10. Yousefi, S.; Green, D.R.; Blaser, K.; Simon, HU. Protein-tyrosine phosphorylation regulates apoptosis in human eosinophils and neutrophils. Proc. Natl. Acad. Sci. USA, 1994, 91, 10868-10872.
11. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103, 193-200.
12. Pavelic, K.; Banjac, Z.; Pavelic, J.; Spaventi, S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anti-Cancer Res., 1993, 13, 1133-1137.
13. Tang, C.K.; Gong, X.Q.; Moscatello, D.K.; Wong, A.J.; Lippman, M.E. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res., 2000, 60, 3081.
14. Huang, S.M.; Harari, P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs, 1999, 17, 259-269.
15. Hong, W.K.; Spitz, M.R.; Lippman, S.M. Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets. J. Clin. Oncol. , 2000, 18, 9S-18S
16. Kleespeis, A.; Ischenko, I.; Eichhorn, M.E.; Seeliger, H.; Amendt, C.; Matell, O.; Jauch, K.W.; Bruns, C.J. Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine. Clin. Cancer Res., 2008, 14, 5426-5436.
17. Fountzilas, G.; Bobos, M.; Kalogera-Fountzila, A.; Xiros, N.; Murray, S.; Linardou, H.; Karayannopoulou, G.; Koutras, A.K.; Bafaloujos, D.; Samantas, E.; Christodoulou, C.; Economopoulos, T.; Kalogeras, K.T.; Kosmidis, P. Gemcitabine combined with gefitinib in patients with inopearable or metastatic pancreatic cancer: a phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest., 2008, 26,784-793.
18. Brell, J.M.; Matin, K.; Evans, T.; Volkin, R.L.; Kiefer, G.J.; Schlesselman, J.J.; Dranko, S.; Rath, L.; Schmotzer, A.; Lenzner, D.; Ramanathan, R.K. Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology, 2009, 76, 270-274.
19. Osada, S.; Imai, H.; Tomita, H.; Tokuyama, Y.; Okumura, N.; Sakashita, F.; Nonaka, K.; Sugiyama, Y. Vascular endothelial growth factor protects hepatoma cells against oxidative stressinduced cell death. J. Gastroenterol. Hepatol., 2006, 21, 988-993.
20. Schomber, T.; Zumsteg, A.; Strittmatter, K.; Crnic, I.; Antoniadis, H.; Littlewood-Evans, A.; Wood, J.; Christofori, G. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK87/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol. Cancer Ther., 2009, 8, 55-63.
21. Hu-Lowe, D.D.; Zou, H.Y.; Grazzini, M.L.; Hallin, M.E.; Wickman, G.R.; Amundson, K.; Chen, J.H.; Rewolinski, D.A.; Yamazaki, S.; Wu, E.Y.; McTigue, M.A.; Murray, B.W.; Kania, R.S.; O'Connor, P.; Shalinsky, D.R.; Bender, S.L. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinase 1, 2, 3. Clin. Cancer Res., 2008, 14, 7272-7283.
22. Smith, V.; Wirth, G.J.; Fiebig, H.H.; Burger, A.M. Tissue microarray of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genomics Proteomics, 2008, 5, 263-273.
23. Ogawa, M.; Nakai, S.; Deguchi, A.; Nonomura, T.; Masaki, T.; Uchida, N.; Yoshiji, H.; Kuriyama, S,; Vitamin K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells. Int. J. Oncol., 2007, 31, 323-331.
24. Verrax, J.; Vanbever, S.; Stockis, J.; Taper, H.; Calderon, PB. Role of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadioneinduced oxidative stress in K562 human chronic myelogenous leukemic cells. Int. J .Cancer, 2007, 120, 1192-1197.
25. Nutter, L.M.; Ngo, E.O.; Fisher, G.R.; Gutierrez, PL. DNA strand scission and free radical production in menadione-treated cells Correlation with cytotoxicity and role of NADPH quinone acceptor oxidoreductase. J. Biol. Chem., 1992, 267, 2474-2479.
26. Chai, Y.C.; Hendrich, S.; Thomas, J.A. Protein S-thiolation in hepatocytes stimulated by t-butyl hydroperoxide, menadione, and neutrophils. Arch. Biochem. Biophys., 1994, 310, 264.
27. Osada, S.; Saji, S.; Osada, K. Critical role of extracellular signalregulated kinase phosphorylation on menadione (vitamin K3) induced growth inhibition. Cancer, 2001, 91, 1156-1165.
28. Osada, S.; Carr, B.I. Mechanism of novel vitamin K analog induced growth inhibition in human hepatoma cell line. J, Hepatol,. 2001, 34, 676-682.
29. Osada, S.; Saji, S. New approach to cancer therapy: The application of signal transduction to anti-cancer drug. Curr. Med. Chem.-Anti-Cancer Agents, 2003, 3, 119-131.
30. Osada, S.; Osada, K.; Carr, B.I. Tumor cell growth inhibition and extracellular signal-regulated kinase (ERK) phosphorylation by novel K vitamins. J. Mol. Biol., 2001, 314, 765-772.
31. Osada, S.; Carr, BI. Critical role of extracellular signal-regulated kinase (ERK) phosphorylation in novel vitamin K analog-induced cell death. Jpn. J. Cancer Res., 2000, 91, 1250-1257.
32. Sarin, S.K.; Kumar, M.; Garg, S.; Hissar, S.; Pandey, C.; Sharma, B.C. High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol., 2006, 21, 1478-1482.
33. Tetef, M.; Margolin, K.; Ahn, C.; Akman, S.; Chow, W.; Leong, L.; Morgan, R.J. Jr.; Raschko, J.; Somlo, G.; Doroshow, J.H. Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Invest. New. Drugs, 1995, 13, 157-162.
34. Lim, D.; Morgan, R.J. Jr.; Akman, S.; Margolin, K.; Carr, B.I.; Leong, L.; Odujinrin, O.; Doroshow, J.H. Phase I trial menadiol diphosphate (vitamin K3) in advanced malignancy. Invest. New Drugs, 2005, 23, 235-239.
35. Taper, H.S. Altered deoxyribonuclease activity in cancer cells and its role in non toxic adjuvant cancer therapy with mixed vitamins C and K3. Anticancer Res., 2008, 28, 2727-2732.
36. Tareen, B.; Summers, J.L.; Jamison, J.M.; Neal, D.R.; McGuire, K.; Gerson, L.; Diokno, A. A 12 week, open label, phase I/II study using apatone for the treatment of prostate cancer patients who have failed standard therapy. Int. J. Med .Sci., 2008, 24, 62-67.
37. Chang, K.J.; Nguyen, P.T.; Thompson, J.A.; Kurosaki, T.T.; Casey, L.R.; Leung, E.C.; Granger, G.A. Phase I clinical trial of allogenic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma. Cancer, 2000, 88, 1325-1335.
38. Pasricha, P.J.; Rai, R.; Ravich, W.J.; Hendrix, T.R.; Kalloo, A.N. Botulinum toxin for achalashia: long- term outcome and predictors of response. Gastroenterology, 1996, 110, 1410-1415.
39. Wiersema, M.; Wiersema, L. Endosonography guided celiac plexus neurolysis (EUS CPN) in patients with pain due to intra-abdominal malignancy. Gastrointest Endosc., 1996, 43, A565.
40. Bhutani, M.S. Endoscopic ultrasound guided antitumor therapy. Endoscopy, 2003, 35, 54-56.
41. Hecht, J.R.; Bedford, R.; Abbruzzese, J.L.; Lahoti, S.; Reid, T.R.; Soetikno, R.M.; Kirn, D.H.; Freeman, S.M. A phase I/II trial of intramural endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res., 2003, 9, 555-561.
42. Klapman, J.B.; Chang, K.J. Endoscopic ultrasound-guided fineneedle injection. Gastrointest Endosc. Clin. N Am., 2005, 15, 168-177.
43. Chang, K.J.; Lee, J.G.; Holcombe, R.F.; Kuo, J.; Muthusamy, R.; Wu, M.L. Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat. Clin. Pract. Gastroenterol. Hepatol., 2008, 5, 107-111.
44. Osada, S.; Sakashita, F.; Hosono, Y.; Nonaka, K.; Tokuyama, Y.; Tanaka, H.; Sasaki, Y.; Tomita, H.; Komori, S.; Matsui, S.; Takahashi, T. Extracellular signal-regulated kinase phosphorylation due to menadione-induced arylation mediates growth inhibition of pancreas cancer cells. Cancer Chemother. Pharmacol., 2008, 62, 315-320.
45. Osada, S.; Tomita, H.; Tanaka, Y.; Tokuyama, Y.; Tanaka, H.; Sakashita, F.; Takahashi, T.; The utility of vitamin K3 (menadione) against pancreatic cancer. Anticancer Res., 2008, 28, 45-50.